I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement